These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 9734938)

  • 21. Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group.
    McCloskey RV; Straube RC; Sanders C; Smith SM; Smith CR
    Ann Intern Med; 1994 Jul; 121(1):1-5. PubMed ID: 8198341
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and efficacy of affinity-purified, anti-tumor necrosis factor-alpha, ovine fab for injection (CytoFab) in severe sepsis.
    Rice TW; Wheeler AP; Morris PE; Paz HL; Russell JA; Edens TR; Bernard GR
    Crit Care Med; 2006 Sep; 34(9):2271-81. PubMed ID: 16810105
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial.
    Tremoulet AH; Jain S; Jaggi P; Jimenez-Fernandez S; Pancheri JM; Sun X; Kanegaye JT; Kovalchin JP; Printz BF; Ramilo O; Burns JC
    Lancet; 2014 May; 383(9930):1731-8. PubMed ID: 24572997
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Candidemia as a cause of septic shock and multiple organ failure in nonimmunocompromised patients.
    Hadley S; Lee WW; Ruthazer R; Nasraway SA
    Crit Care Med; 2002 Aug; 30(8):1808-14. PubMed ID: 12163798
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group.
    Greenman RL; Schein RM; Martin MA; Wenzel RP; MacIntyre NR; Emmanuel G; Chmel H; Kohler RB; McCarthy M; Plouffe J
    JAMA; 1991 Aug; 266(8):1097-102. PubMed ID: 1865542
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of immunomodulating therapy on morbidity in patients with severe sepsis.
    Pittet D; Harbarth S; Suter PM; Reinhart K; Leighton A; Barker C; Macdonald F; Abraham E
    Am J Respir Crit Care Med; 1999 Sep; 160(3):852-7. PubMed ID: 10471608
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Survival of primates in LD100 septic shock following therapy with antibody to tumor necrosis factor (TNF alpha).
    Hinshaw LB; Tekamp-Olson P; Chang AC; Lee PA; Taylor FB; Murray CK; Peer GT; Emerson TE; Passey RB; Kuo GC
    Circ Shock; 1990 Mar; 30(3):279-92. PubMed ID: 2178801
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of monoclonal antibody against tumor necrosis factor alpha in an endotoxemic baboon model.
    Emerson TE; Lindsey DC; Jesmok GJ; Duerr ML; Fournel MA
    Circ Shock; 1992 Oct; 38(2):75-84. PubMed ID: 1423924
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The French National Registry of HA-1A (Centoxin) in septic shock. A cohort study of 600 patients. The National Committee for the Evaluation of Centoxin.
    Arch Intern Med; 1994 Nov; 154(21):2484-91. PubMed ID: 7979845
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of aging on circulating levels of proinflammatory cytokines during septic shock. Norasept II Study Investigators.
    Marik PE; Zaloga GP;
    J Am Geriatr Soc; 2001 Jan; 49(1):5-9. PubMed ID: 11207836
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluating the efficacy and safety of two doses of the polyclonal anti-tumor necrosis factor-α fragment antibody AZD9773 in adult patients with severe sepsis and/or septic shock: randomized, double-blind, placebo-controlled phase IIb study*.
    Bernard GR; Francois B; Mira JP; Vincent JL; Dellinger RP; Russell JA; Larosa SP; Laterre PF; Levy MM; Dankner W; Schmitt N; Lindemann J; Wittebole X
    Crit Care Med; 2014 Mar; 42(3):504-11. PubMed ID: 24335445
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiovascular effects of the nitric oxide synthase inhibitor NG-methyl-L-arginine hydrochloride (546C88) in patients with septic shock: results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002).
    Watson D; Grover R; Anzueto A; Lorente J; Smithies M; Bellomo R; Guntupalli K; Grossman S; Donaldson J; Le Gall JR;
    Crit Care Med; 2004 Jan; 32(1):13-20. PubMed ID: 14707555
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of corticotropin-releasing hormone on proopiomelanocortin derivatives and monocytic HLA-DR expression in patients with septic shock.
    Matejec R; Kayser F; Schmal F; Uhle F; Bödeker RH; Maxeiner H; Kolbe JA
    Peptides; 2013 Sep; 47():133-41. PubMed ID: 23891702
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vivo blockade of tumor necrosis factor-alpha in patients with rheumatoid arthritis: longterm effects after repeated infusion of chimeric monoclonal antibody cA2.
    Lorenz HM; Grünke M; Hieronymus T; Antoni C; Nüsslein H; Schaible TF; Manger B; Kalden JR
    J Rheumatol; 2000 Feb; 27(2):304-10. PubMed ID: 10685789
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vivo blockade of TNF-alpha by intravenous infusion of a chimeric monoclonal TNF-alpha antibody in patients with rheumatoid arthritis. Short term cellular and molecular effects.
    Lorenz HM; Antoni C; Valerius T; Repp R; Grünke M; Schwerdtner N; Nüsslein H; Woody J; Kalden JR; Manger B
    J Immunol; 1996 Feb; 156(4):1646-53. PubMed ID: 8568271
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors.
    Genovese MC; Fleischmann RM; Greenwald M; Satterwhite J; Veenhuizen M; Xie L; Berclaz PY; Myers S; Benichou O
    Ann Rheum Dis; 2013 Sep; 72(9):1461-8. PubMed ID: 23268367
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influence of N-acetylcysteine on indirect indicators of tissue oxygenation in septic shock patients: results from a prospective, randomized, double-blind study.
    Spies CD; Reinhart K; Witt I; Meier-Hellmann A; Hannemann L; Bredle DL; Schaffartzik W
    Crit Care Med; 1994 Nov; 22(11):1738-46. PubMed ID: 7956276
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adrenal insufficiency occurring during septic shock: incidence, outcome, and relationship to peripheral cytokine levels.
    Soni A; Pepper GM; Wyrwinski PM; Ramirez NE; Simon R; Pina T; Gruenspan H; Vaca CE
    Am J Med; 1995 Mar; 98(3):266-71. PubMed ID: 7872343
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical safety, tolerability, and pharmacokinetics of murine monoclonal antibody to human tumor necrosis factor-alpha.
    Saravolatz LD; Wherry JC; Spooner C; Markowitz N; Allred R; Remick D; Fournel M; Pennington JE
    J Infect Dis; 1994 Jan; 169(1):214-7. PubMed ID: 8277186
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.
    Maini RN; Breedveld FC; Kalden JR; Smolen JS; Davis D; Macfarlane JD; Antoni C; Leeb B; Elliott MJ; Woody JN; Schaible TF; Feldmann M
    Arthritis Rheum; 1998 Sep; 41(9):1552-63. PubMed ID: 9751087
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.